iifl-logo-icon 1

Sandu Pharmaceuticals Ltd Share Price

59.55
(-1.44%)
Jul 23, 2024|10:37:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open59.6
  • Day's High59.6
  • 52 Wk High85
  • Prev. Close60.42
  • Day's Low59.4
  • 52 Wk Low50.1
  • Turnover (lac)0.56
  • P/E40.01
  • Face Value10
  • Book Value32.86
  • EPS1.51
  • Mkt. Cap (Cr.)57.53
  • Div. Yield0
No Records Found

Sandu Pharmaceuticals Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

59.6

Prev. Close

60.42

Turnover(Lac.)

0.56

Day's High

59.6

Day's Low

59.4

52 Week's High

85

52 Week's Low

50.1

Book Value

32.86

Face Value

10

Mkt Cap (₹ Cr.)

57.53

P/E

40.01

EPS

1.51

Divi. Yield

0

Sandu Pharmaceuticals Ltd Corporate Action

14 Aug 2023

12:00 AM

BookCloser

arrow

31 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

12 Aug 2023

12:00 AM

AGM

Announcement Date: 12 Aug, 2023

arrow

12 Aug 2023

12:00 AM

Dividend

Dividend Amount: 0.75

Record Date: 19 Sep, 2023

arrow

Sandu Pharmaceuticals Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Sandu Pharmaceuticals Ltd SHAREHOLDING SNAPSHOT

23 Jul, 2024|10:48 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 42.90%

Foreign: 0.00%

Indian: 42.90%

Non-Promoter- 0.01%

Institutions: 0.00%

Non-Institutions: 57.09%

Custodian: 0.00%

Share Price

Sandu Pharmaceuticals Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

9.66

9.25

8.82

7.08

Preference Capital

0

0

0

0

Reserves

29.58

27.22

24.67

22.16

Net Worth

39.24

36.47

33.49

29.24

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Revenue

58.75

48.36

49.01

42.82

yoy growth (%)

21.47

-1.32

14.45

4.25

Raw materials

-34.5

-25.11

-28.39

-25.63

As % of sales

58.71

51.92

57.92

59.86

Employee costs

-8.01

-6.85

-5.93

-5.41

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2021Mar-2020Mar-2018Mar-2017

Profit before tax

1.68

0.92

0.75

-0.03

Depreciation

-0.55

-0.55

-0.6

-0.86

Tax paid

-0.58

-0.19

-0.19

-0.49

Working capital

5.71

-2.3

-5.65

-2.17

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2021Mar-2020Mar-2018Mar-2017

Growth matrix (%)

Revenue growth

21.47

-1.32

14.45

4.25

Op profit growth

48.33

-40.99

33.22

-36.08

EBIT growth

32.42

-31.72

36.55

-38.08

Net profit growth

51.66

28.27

-226.4

-182.58

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022

Gross Sales

67.28

65.35

65.5

Excise Duty

0

0

0

Net Sales

67.28

65.35

65.5

Other Operating Income

0

0

0

Other Income

0.42

0.33

0.08

Sandu Pharmaceuticals Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,587.9

124.833,80,990.4867.60.855,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,534.75

76.421,20,383.365310.662,259507.93

Cipla Ltd

CIPLA

1,489.7

32.381,20,295.961,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,154.4

33.791,16,159.651,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,769.25

26.361,12,931.21,034.80.595,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT Sandu Pharmaceuticals Ltd

Management

Register Office

Registrar Office

Non-Exec. & Independent Dir.

Dilip R Salgaocar

Non-Exec. & Independent Dir.

Krishna B Deshpande

Non-Exec. & Independent Dir.

Madan Laxman Kapre

Chairman & Independent Directo

K Vinay Kumar

Non-Exec & Non-Independent Dir

Shashank B Sandu

Managing Director

Umesh B Sandu

Non-Exec & Non-Independent Dir

Shubhada P Sandu

Company Sec. & Compli. Officer

Pratika Mhambray

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Sandu Pharmaceuticals Ltd (SPL) was established in 1985. The Company is mainly engaged in the business of manufacturing and trading of Ayurvedic medicines under the brand name SANDU.SPL came out with a public issue of 17.70 lac equity shares at par, aggregating Rs 1.77 cr, in Sep.94, to part-finance its new project in Goa costing Rs 7.28 cr to manufacture ayurvedic medicines and formulations. This plant employs the latest material handling systems and other modern machinery and has the most hygienic production facilities to attain the highest possible quality standards. Ayurvedic products have a very good market in India and abroad due to their minimal side effects.The company commenced commercial production of Ayurvedic Medicines & Formulations, at the Goa plant in 1996-97. Thereafter, it commenced production of manufacturing Unit II in Goa from May, 2002.
Read More

Company FAQs

What is the Sandu Pharmaceuticals Ltd share price today?

Down Arrow

The Sandu Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹59.55 today.

What is the Market Cap of Sandu Pharmaceuticals Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sandu Pharmaceuticals Ltd is ₹57.53 Cr. as of 23 Jul ‘24

What is the PE and PB ratio of Sandu Pharmaceuticals Ltd?

Down Arrow

The PE and PB ratios of Sandu Pharmaceuticals Ltd is 40.01 and 1.84 as of 23 Jul ‘24

What is the 52 Week High and Low of Sandu Pharmaceuticals Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Sandu Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Sandu Pharmaceuticals Ltd is ₹50.1 and ₹85 as of 23 Jul ‘24

What is the CAGR of Sandu Pharmaceuticals Ltd?

Down Arrow

Sandu Pharmaceuticals Ltd's CAGR for 5 Years at 27.19%, 3 Years at 1.81%, 1 Year at 16.44%, 6 Month at -13.72%, 3 Month at -2.42% and 1 Month at 1.58%.

What is the shareholding pattern of Sandu Pharmaceuticals Ltd?

Down Arrow

The shareholding pattern of Sandu Pharmaceuticals Ltd is as follows:
Promoters - 42.90 %
Institutions - 0.01 %
Public - 57.09 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.